Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Caminero

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of the Neurological Sciences|August 5, 2011
Sleep disturbances in multiple sclerosisAna Caminero, Manuel Bartolomé
Journal of Neuroimmunology|April 9, 2011
Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing storyAna Caminero, Manuel Comabella, Xavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2012
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur, Mar Tintoré, Angela Vidal-Jordana, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Revista De Neurologia|February 11, 2010
[Zonisamide in the preventive treatment of refractory migraine]Julio Pascual-Gómez, Manuel Gracia-Naya, Rogelio Leira, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 5, 2016
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatusMaria Sepúlveda, Thaís Armangué, Nuria Sola-Valls, et al.
Frontiers in Immunology|November 28, 2024
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosisFernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, et al.
Frontiers in Immunology|January 3, 2025
Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosisFernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the Neurological Sciences|August 5, 2011
Sleep disturbances in multiple sclerosisAna Caminero, Manuel Bartolomé
Journal of Neuroimmunology|April 9, 2011
Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing storyAna Caminero, Manuel Comabella, Xavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2012
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur, Mar Tintoré, Angela Vidal-Jordana, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Revista De Neurologia|February 11, 2010
[Zonisamide in the preventive treatment of refractory migraine]Julio Pascual-Gómez, Manuel Gracia-Naya, Rogelio Leira, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 5, 2016
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatusMaria Sepúlveda, Thaís Armangué, Nuria Sola-Valls, et al.
Frontiers in Immunology|November 28, 2024
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosisFernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, et al.
Frontiers in Immunology|January 3, 2025
Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosisFernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, et al.
Pageof 1